Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176500 | 0.90 | ANPEP (0.33) | ANPEPERAP2EPHX1 | |
| SCHEMBL5529429 | 0.90 | ANPEP (0.33) | ANPEPERAP2EPHX1 | |
| SCHEMBL7176498 | 0.90 | ANPEP (0.33) | ANPEPERAP2EPHX1 | |
| SCHEMBL5394771 | 0.80 | TP53 (0.45) | ALDH1A1ANPEPERAP2TP53KDM4E | |
| SCHEMBL5388081 | 0.78 | TP53 (0.48) | ALDH1A1ANPEPERAP2TP53KDM4E | |
| SCHEMBL5394744 | 0.78 | TP53 (0.48) | ALDH1A1ANPEPERAP2TP53KDM4E | |
| SCHEMBL6056274 | 0.77 | ANPEP (0.37) | ALDH1A1ANPEPERAP2 | |
| SCHEMBL6056283 | 0.77 | ANPEP (0.37) | ALDH1A1ANPEPERAP2 | |
| SCHEMBL5537099 | 0.77 | ANPEP (0.37) | ALDH1A1ANPEPERAP2 | |
| SCHEMBL8148562 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | ALDH1A1 268/4885ANPEP 2033/4885ERAP2 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.